Brand dynamics
Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health
Another leap! Lizhu Group's MSCI ESG rating has been upgraded to AA.
Published Time：
2022-08-02
Recently, MSCI (Morgan Stanley Capital International), a leading international index company, announced its latest annual ESG (Environmental, Social and Governance) ratings. Thanks to its excellent ESG management and performance in 2021, in July 2022, Lizhu Group's MSCI ESG rating was upgraded two levels from BBB to AA. Its ratings for "Product Safety and Quality" and "Pollutant and Waste Emissions" are among the best in the global industry.
Lizhu Group's board of directors attaches great importance to and continuously improves its ESG governance framework and management mechanisms. On June 30, 2020, an ESG committee under the board of directors was established, chaired by the company's chairman, with an ESG working group serving as its executive body. The ESG committee is responsible for formulating the company's ESG goals and strategies, overseeing the ESG management framework and operations, assessing ESG risks and opportunities, and continuously strengthening the Group's ESG work through the supervision and management of ESG goals.
In 2021, Lizhu Group launched multi-level improvement actions across the Group, covering various aspects of enterprise operation management, including environmental protection, product quality and safety, business ethics, whistleblower protection, supplier quality management, sustainable supply chain, responsible marketing, and universal health, comprehensively optimizing the Group's governance and sustainable operation capabilities.
In 2021, Lizhu Group established new carbon reduction targets for 2021-2025 and a carbon neutrality target for 2055. Referencing TCFD recommendations for managing climate change risks, it guided the company in the refined management of pollutant emissions and resource utilization, achieving a 6.7% year-on-year decrease in greenhouse gas emissions. All of the Group's production enterprises have obtained ISO 14001 environmental management system certification. The Group has also established a linkage system between ESG performance and management compensation, ensuring the achievement of environmental management goals through effective incentive mechanisms and promoting green and low-carbon operations.
At the same time, Lizhu Group strives to create a diverse, inclusive, and unbiased friendly work atmosphere, adhering to the core conventions of the International Labour Organization and establishing labor employment and ethical conduct standards. In 2021, women accounted for approximately 48% of the Group's employees, and 35% of managers and above were women. The Group has set targets for future female employee representation of no less than 40% and for the board of directors to include at least one female member.
Lizhu Group has always operated with a mission of "Patient life quality first" and a vision of "Being a leader in the pharmaceutical industry" While pursuing its own sustainable development, it has always actively practiced corporate social responsibility, giving back to society, contributing to rural revitalization, and promoting common prosperity. In the future, Lizhu Group will continue to implement its ESG development strategy, actively promoting the Group's sustainable development in areas such as carbon peaking, carbon neutrality, and biodiversity conservation.
MSCI is one of the world's most influential capital market rating agencies. Its ratings are the most widely used reference standard by global institutional investors, and its ESG ratings have become an important basis for decision-making by major global investment institutions. MSCI's ESG ratings cover more than 8,500 listed companies, evaluating them based on publicly available information on 35 key ESG issues. The ratings have become an important basis for major asset management institutions worldwide in making investment decisions, as well as an important parameter for corporate governance that is closely watched by domestic regulatory agencies and investors.
Quick Navigation
+86 755-33268688 | Service Hotline
Official WeChat Official Account
Copyright © 2025 Joincare Pharmaceutical Group Industry Co., Ltd. ALL Rights Reserve.